MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
Brain cancer awareness, grey ribbon on helping hand

MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing dealLarge…

Continue Reading
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
3d rendered medically accurate illustration of white blood cells attacking a cancer cell

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International Convention BUFFALO, N.Y., May 29, 2019 /PRNewswire/ -- MimiVax LLC, a clinical-stage…

Continue Reading
SurVaxM Phase I Completed
A syringe with the needle point to the vaccine vial on the colorful abstract background

SurVaxM Phase I Completed

Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in…

Continue Reading